Imaging Science and Photochemistry ›› 2020, Vol. 38 ›› Issue (2): 301-306.DOI: 10.7517/issn.1674-0475.190916

• Review and Articles • Previous Articles     Next Articles

Clinical Effect of Modified Panretinal Photocoagulation on Diabetic Retinopathy and Its Effect on Serum Level of Vascular Endothelial Growth Factor

XU Jianlong1, MA Qing2   

  1. 1. Department of Ophthalmology, The Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, Hebei, P. R. China;
    2. Department of Laboratory Teaching and Research Section, Xingtai Medical College, Xingtai 054000, Hebei, P. R. China
  • Received:2019-09-18 Online:2020-03-15 Published:2020-03-15
  • Supported by:
     

Abstract: To investigate the clinical effect of modified panretinal photocoagulation in the treatment of diabetic retinopathy (DR) and its effect on serum vascular endothelial growth factor (VEGF), this study selected 168 DR patients (212 eyes) admitted to our hospital from January 2018 to January 2019 were randomly divided into control group and observation group, 84 cases (106 eyes) in each group. The control group was treated with whole retina laser photocoagulation, while the observation group was treated with improved whole retina laser photocoagulation. The interval of photocoagulation therapy was 1 week, the treatment lasted 4 weeks. Following up for 6 months, the clinical effects of the two groups were observed; Before and after treatment, the best corrected visual acuity, intraocular pressure, retinal capillary non-perfusion area and regression of neovascularization were compared, and serum levels of vascular endothelial growth factor and ET-1 were compared. 6 months after treatment, the total effective rate of the observation group (92.45%) was significantly higher than that of the control group (75.47%), and the difference was statistically significant (P<0.05). There was no significant difference in the best corrected visual acuity and intraocular pressure between the two groups before and after treatment (P>0.05). Retinal capillary non-perfusion area and the regression rate of neovascularization in the observation group were significantly higher than those in the control group (P<0.05). The levels of serum VEGF and ET-1 in both groups were lower than those before treatment, and the levels of serum VEGF and ET-1 in the observation group were significantly lower than those in the control group (P<0.05). During the follow-up period, no serious complications such as visual acuity decrease, intraocular pressure increase, macular edema increase or vitreous hemorrhage occurred in both groups. The results show that, the modified panretinal photocoagulation is safe and effective in the treatment of DR. It is helpful to promote the regression of retinal non-perfusion area and neovascularization, reduce the level of vascular endothelial growth factor, improve the status of retinal ischemia and hypoxia, and control the further development of retinal lesions.

 

Key words: diabetic retinopathy(DR), modified panretinal photocoagulation, vascular endothelial growth factor

CLC Number: